Dominantly Inherited Alzheimer Disease (DIAD) research hub

The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Amyloid Removal Trial (ART): A Phase IIIb/IV Open-Label Study of Lecanemab to Evaluate Prevention and Progression of Dominantly Inherited Alzheimer’s Disease

This study looks at a new drug, lecanemab, for people with a rare, inherited form of Alzheimer's disease. It aims to see if the drug can prevent or slow down the disease by checking for changes in the brain and memory over time.